# BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia

> **NCT06746519** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chen Suning** · enrollment: 135 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** BN104 combined Intensive Chemotherapy or Venetoclax/Azacitidine

## Key facts

- **NCT ID:** NCT06746519
- **Lead sponsor:** Chen Suning
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-25
- **Primary completion:** 2025-12-30
- **Final completion:** 2027-06-30
- **Target enrollment:** 135 (ESTIMATED)
- **Last updated:** 2024-12-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06746519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06746519, "BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06746519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*